<DOC>
	<DOCNO>NCT01521364</DOCNO>
	<brief_summary>Future patient might benefit combination linezolid ( LIN ) clarithromycin ( CLA ) treatment Multidrug-resistant Extensively Drug-resistant Tuberculosis ( MDR/XDR-TB ) due possible synergistic activity show vitro experiment different Mycobacteria strain . The investigator observe increased LIN serum level three case combine LIN CLA investigator describe one case report ( Bolhuis et al ) . The investigator suggest conduct prospective pharmacokinetic study MDR- XDR-TB patient quantify describe interaction LIN CLA .</brief_summary>
	<brief_title>Drug Interaction Study Between Linezolid Clarithromycin Tuberculosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Extensively Drug-Resistant Tuberculosis</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Age â‰¥18 year old Signed informed consent Diagnosis MDR/XDRTB confirm standard microbiological criterion ( culturebased , molecular ) Treatment linezolid 300mg twice daily per o . Hypersensitivity : linezolid , clarithromycin , erythromycin , macrolide antibiotic , excipients linezolid clarithromycin . Concomitant use astemizole , cisapride , ergotamine derivative ( dihydroergotamine , ergotamine ) , monoamine oxidase inhibitor ( phenelzine , isocarboxazid , selegiline , moclobemide ) , pimozide , terfenadine . Pregnancy breastfeed . Hypokalemia Concomitant use Pgp inhibitors/inducers , e.g . amiodarone , verapamil , digoxin , tipranavir/ritonavir , lovastatin , tariquidar , itraconazole , dipyridamol , erythromycin , ritonavir , quinidine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>drug-interaction</keyword>
	<keyword>linezolid</keyword>
	<keyword>clarithromycin</keyword>
	<keyword>Mycobacterium tuberculosis</keyword>
</DOC>